Switch theme
Sign up to access all valuation multiples
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI.
2015
n/a
Last FY Revenue $0.8M
Last FY EBITDA -$4.4M
$110M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Oncocross achieved revenue of $0.8M and an EBITDA of -$4.4M.
Oncocross expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncocross valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 67% | XXX | XXX | XXX |
| EBITDA | XXX | -$4.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -565% | XXX | XXX | XXX |
| EBIT | XXX | -$5.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -650% | XXX | XXX | XXX |
| Net Profit | XXX | -$4.7M | XXX | XXX | XXX |
| Net Margin | XXX | -605% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Oncocross's stock price is KRW 14110 (or $10).
Oncocross has current market cap of KRW 167B (or $122M), and EV of KRW 151B (or $110M).
See Oncocross trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $110M | $122M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Oncocross has market cap of $122M and EV of $110M.
Oncocross's trades at 140.6x EV/Revenue multiple, and -24.9x EV/EBITDA.
Equity research analysts estimate Oncocross's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncocross's P/E ratio is not available.
See valuation multiples for Oncocross and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 140.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -24.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -21.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -25.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -26.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncocross's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Oncocross's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncocross's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncocross and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -565% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 245% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 717% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncocross acquired XXX companies to date.
Last acquisition by Oncocross was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncocross acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Oncocross founded? | Oncocross was founded in 2015. |
| Where is Oncocross headquartered? | Oncocross is headquartered in South Korea. |
| Is Oncocross publicy listed? | Yes, Oncocross is a public company listed on KRX. |
| What is the stock symbol of Oncocross? | Oncocross trades under 382150 ticker. |
| When did Oncocross go public? | Oncocross went public in 2024. |
| Who are competitors of Oncocross? | Similar companies to Oncocross include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Oncocross? | Oncocross's current market cap is $122M |
| Is Oncocross profitable? | Yes, Oncocross is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
